Imunon Inc (IMNN)

Imunon Secures $10 Million Funding Package to Advance Phase 3 Ovarian Cancer Study (IMNN)June 4, 2026 10:32 AM
IH Market News Imunon Inc. (NASDAQ:IMNN) traded higher in premarket dealings on Thursday after announcing a $10 million financing package that will support the continued development of its lead ovarian cancer programme. Shares of the clinical-stage biotechnology company rose 3.3% following the news. Funding to Support Pivotal OVATION 3 Trial The newly secured capital will primarily be used to advance enrollment in Imunon’s Phase 3 OVATION 3 clinical study. The trial is evaluating IMNN-001 in patients newly diagnosed with advanced ovarian cancer and represents a key stage in the company’s development strategy. Management said the financing strengthens its ability to continue executing the study while progressing toward future clinical milestones. Financing Structure Includes Preferred Shares and Debt Under the agreement, Imunon will receive funding through a combination of preferred equity and secured debt. The transaction includes the issuance of 250 shares of non-redeemable, non-convertible preferred stock for gross proceeds of $2.5 million, alongside two secured promissory notes totaling approximately $7.72 million. The notes carry annual interest rates of 8% and 5% and are scheduled to mature 18 months after issuance. Encouraging Survival Data Supports Development The financing follows the release of updated Phase 2 clinical results for IMNN-001. According to the company, median overall survival among women with newly diagnosed advanced ovarian cancer treated with IMNN-001 alongside standard chemotherapy increased to 14.7 months, compared with the previously reported improvement of 11.1 months. Patients who also received PARP inhibitor therapy demonstrated an even stronger outcome, achieving a median overall survival benefit of 24.2 months versus standard chemotherapy alone. The updated findings have strengthened the scientific rationale behind the ongoing Phase 3 programme. Designed to Limit Shareholder Dilution Imunon noted that the financing structure differs from many traditional equity raises because it does not include warrants and avoids the deep discounts often associated with public offerings. Management believes the approach provides access to capital while helping protect existing shareholders from excessive dilution. Stacy R. Lindborg, President and Chief Executive Officer of Imunon, said the arrangement gives the company greater control over its funding needs while supporting long-term value creation. Balance Sheet Strengthened Ahead of Key Milestones The company said the transaction is intended to reinforce its financial position as it works toward completing patient enrollment in the OVATION 3 trial. With additional capital now secured, Imunon aims to maintain momentum in its late-stage clinical programme and continue advancing IMNN-001 as a potential treatment option for patients with advanced ovarian cancer. Imunon stock price Original: Imunon Secures $10 Million Funding Package to Advance Phase 3 Ovarian Cancer Study (IMNN)

Phase 2 ovarian $5.69

Happy to buy more whenever possible. 

IMNN...............................................................................p/m

https://investors.imunon.com/node/21096/pdf

IMNN...............................https://stockcharts.com/h-sc/ui?s=IMNN&p=W&b=5&g=0&id=p86431144783

Market OutlookThe bulls have taken full control of the market. The negative sentiment that led to the last bearish pattern has dissipated. The current price is significantly distant from the confirmation level, greatly reducing the chances of a bearish confirmation. Besides, the signal is suggesting to STAY LONG. It is prudent to follow the signal and continue holding this security. The Delayed Intraday Module is OFF.

Market Outlook IMNNThe bulls have compelling evidence supporting their stance, prompting us to consider placing a bullish bet. Today’s candlestick has a white body and its close is above the confirmation level. The bullish pattern that was previously identified is finally confirmed and a BUYsignal is generated. Now may be the opportune moment to join this upswing and capitalize on the bullish market sentiment. The market is signaling a potential new profit opportunity. Don't let this opportunity slip through your fingers.

Market Outlook"Alarm bells are ringing for those holding short positions. We are on the brink of concluding the bearish phase in the market and recognizing the dominance of the bulls. The share price is above the confirmation level of the last bullish pattern"

Who bought much higher?
CLSN?

Pfizer could use some IMNN right now   

cant p/m you but….

…

GTI looks pretty solid for a friday before a holiday (mon closed). it ran to about 1.80 in jan and has been inching up. watch that one.

+>>> IMNN - they have partnership the KOCH Institute for Cancer Research which was founded by David Koch!

Dollar Volume and incredible bids indicate to me this is moving higher after some consolidation!

Happy Trading

CC

$IMNN: What is this I'm hearing......... KOCH involved ???

Someone wanna elaborate on this ?
Rumors spreading that the KOCHs of Koch Industries have something to do here ... I don't know the details
just wanna find out whats going.
If you know something.......... Say Something.

THANKS


GO $IMNN

Come on Friday squeeze!

$IMNN: Boooommmmmmmmm......... $1.40

Who's winning this TGIF ????????????

GO $IMNN

IMNN................................p/m news.........................

IMNN nice news https://ih.advfn.com/stock-market/NASDAQ/imunon-IMNN/stock-news/96117547/imunon-announces-2025-asco-annual-meeting-oral-pre

Hit 1.02 trading freely after mkt

Overdue for some company news imho. 
Happy trading. 

Definitely has potential. I’m here for the ride. I know that.

Looks good

2000 at 1.00 lol down again lmfao

Grabbbed some .95s ..500 of them ;) 

seems to have settled around low nineties. nice am news...good entry impo - best wishes all

Accumulation phase over imho. Time to rise. 

.92-.99 zone breaks then $1-$1.35 next

Ready per FDA for phase 3 trials 2025
.91 + 12%

IMNN under $2

IMNN..........................https://stockcharts.com/h-sc/ui?s=IMNN&p=W&b=5&g=0&id=p86431144783

IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

No midday offering.

Instead ....

Offering next morning at $2

Got really lucky yesterday. Bought/sold for $2,000 profit.
Didn’t want to hold overnight due to significant concern about imminent financing.
I was proven correct this morning.
IMNN down 40% Premarket to $1.85.
Unreal.

$IMNN +161%+ #DDAmanda Video Analysis - #1 Stock Scanner/Screener



Z

IMNN new 52 week high will the gap get filled

ATNF Next WINT Sub Million Float INMM Congrads to all you longs today nice

I want to trade this, but so many midday offerings lately.

IMNN..............................................https://stockcharts.com/h-sc/ui?s=IMNN&p=W&b=5&g=0&id=p86431144783

IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001

NEW HIGHS

Yikes

$IMNN With not overwhelming positive news, keeping a close eye on for testing any of these levels pic.twitter.com/sIA5t4Auq6— Isai Bonilla (@isai_bonilla21) July 29, 2024

you got competition https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174831139

IMNN..........................https://stockcharts.com/h-sc/ui?s=IMNN&p=W&b=5&g=0&id=p86431144783

IMNN under $2

IMNN...................https://stockcharts.com/h-sc/ui?s=IMNN&p=W&b=5&g=0&id=p86431144783

IMNN........................................https://stockcharts.com/h-sc/ui?s=IMNN&p=W&b=5&g=0&id=p86431144783

Could be a nice little bump tomorrow after fins

IMNN new 52 week low

IMNN new 52 week low